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Abstract 
 
Infrared spectroscopy is a reliable, rapid and cost effective characterisation technique, 
delivering a molecular finger print of the sample. It is expected that its sensitivity would 
enable detection of small chemical variations in biological samples associated with disease. 
ATR-IR is particularly suitable for liquid sample analysis and, although air drying is 
commonly performed before data collection, just a drop of human serum is enough for 
screening and early diagnosis. However, the dynamic range of constituent biochemical 
concentrations in the serum composition remains a limiting factor to the reliability of the 
technique. Using glucose as a model spike in human serum, it has been demonstrated in the 
present study that fractionating the serum prior to spectroscopic analysis can considerably 
improve the precision and accuracy of quantitative models based on the Partial Least Squares 
Regression algorithm. By depleting the abundant high molecular weight proteins, which 
otherwise dominate the spectral signatures collected, the ability to monitor changes in the 
concentrations of the low molecular weight constituents is enhanced. The Root Mean Square 
Error for the Validation set (RMSEV) has been improved by a factor of 5 following human 
serum processing with an average relative error in the predictive values below 1% is 
achieved. Moreover, the approach is easily transferable to different bodily fluids, which 
would support the development of more efficient and suitable clinical protocols for 
exploration of vibrational spectroscopy based ex-vivo diagnostic tools. 
 
 
  
  
1.  Introduction 
 
Bodily fluids have become a much investigated source of samples for the development of 
rapid and cost effective diagnostic methods
1-4
. Reducing the invasiveness of the current 
approaches to get molecular information linked to pathological events occurring in different 
organs affected by various diseases is naturally one of main challenges to improve the 
patients’ comfort. Therefore, performing analysis directly on a few microliters of serum, 
plasma, saliva or urine has attracted great interest in the medical field, especially due to the 
facile specimen collection. Blood analysis still holds much promise for accurate ex vivo 
diagnostics and, compared to deep tissue biopsies, often requiring extreme interventions, the 
reduced invasiveness of the syringe remains a quite acceptable alternative.  
Human serum (or plasma) is a vast reservoir for biochemical products collected and 
accumulated while perfusing the different organs of the body
5
, ultimately reflecting the 
physiological status of a patient. It is expected that modifications in its overall composition 
could indicate the presence of disease and consequently deliver a diagnostic based on specific 
molecular signatures
6
. It is well accepted that proteins secreted and shed from cells and 
tissues, such as prostate-specific antigen (PSA) and CA125, can be identified routinely and 
act as biomarkers of disease
7
. In addition, proteolysis within the tissue or deregulated post-
translational events participate in fragmentation of proteins produced in tumours that diffuse 
into the circulation
6
. This is further supported by recent associations of pathological 
conditions with small protein and peptide profiles in serum, notably for diabetes
8
, 
cardiovascular or infectious diseases
9
. The number of studies related to serum proteomics, 
peptidomics or metabololics has literary exploded in the literature, complex analytical 
techniques such as chromatography and/or mass spectroscopy being the reference tools
10, 11
. 
Quite naturally, vibrational spectroscopy, which has been widely employed in biomedical 
analysis, from tissue sections
12, 13
 to single cells
14, 15
 with a well demonstrated potential for 
diagnosis
16, 17
, has the capability to become the next generation gold standard tool for serum 
based patient screening
18-20
. The advent of imaging technologies coupled to the rapid data 
collection offered by FTIR systems has contributed considerably to the attraction of infrared 
absorption spectroscopy for biomedical applications
21-23
. However, other methods such as 
ATR-FTIR are highly suitable for analysis of liquid samples, such as body fluids, allowing 
delivery of chemical fingerprints from micro-deposition of the samples directly on the 
Attenuated Total Reflection (ATR) crystal
24, 25
. The IR spectrum contains rich and specific 
information about the molecular composition of the human serum which, coupled to 
advanced multivariate analysis tools, could deliver accurate diagnostics. Recent systematic 
studies have demonstrated the potential of IR serum based diagnosis with different data 
mining approaches such as Principal Components Analysis (PCA), PCA coupled to Linear 
Discriminant Analysis (PCA-LDA), Random Forest or Support Vector Machine (SVM)
26-30
. 
However, the development of spectroscopic technologies with medical perspectives needs to 
align with clinical requirements to enable clinical translation of these promising 
technologies
31
. Although infrared and Raman spectroscopy have great potential for serum 
based detection of disease biomarkers
32, 33
, in many cases, detection of the presence of a 
biomarker is not sufficient, but rather quantification within a physiologically relevant range is 
required, a common example being glucose levels in blood.
34
.   
Partial Least Squares Regression analysis (PLSR) remains one of most used analysis methods 
for quantitative models
35
 either in different body fluids such as urine
36
, saliva
37, 38
, serum
39
 or 
to evaluate physiological responses to drugs in cells
40
. However, the serum composition is 
highly complex, with up to 10,000 different proteins in an overall concentration ranging from 
60 to 80 mg/mL. Moreover, other circulating molecular species such as sugars, lipids, 
peptides, metabolites are present, adding to the complexity of the mixture and consequently 
making quantitative analysis of variations in individual constituents a challenging task. 
Human serum is also characterized by the dynamic range of concentrations observed between 
the abundant, high molecular weight (HMW) and the sparse, low molecular weight (LMW) 
molecules. For example, human serum albumin (HSA) (57–71%) and globulins (8–26%) are 
two abundant HMW proteins completely dominating the composition of the serum 
quantitatively, potentially impacting the detection and monitoring small variations in the 
features related to the presence of the informative low molecular weight 
proteins/peptides/metabolites
41
. The analytical capabilities of traditional proteomic methods 
are limited, given this large dynamic range of concentrations in the serum. Therefore, 
depletion of the highly abundant proteins is now recognized as the first step, yet to be 
optimized, in the analysis of the serum composition
42
. ATR-FTIR suffers from similar 
limitations to those encountered with chromatography and/or mass spectroscopy based 
approaches, which can be overcome by means of sample fractionation prior to data 
recording
24
. Including a separation step prior to IR analysis in order to enhance the specificity 
and sensitivity have been proposed trough coupling with chromatography technologies such 
as LC-IR and GC-IR
43
. Those hyphenated approaches have been reported in chemistry, 
pharmaceutical and food sciences applications
44-46
. However, the development of cryogenic 
temperature control methods during the sample preparation remains the most promising 
aspect for possible emergence of such technologies in biomedical applications and human 
body fluids analysis
47
. This present study however investigates the benefits of an alternative 
approach combining centrifugal filtration/fractionation with ATR-IR spectroscopy for the 
analysis of human serum as a proof of principle for monitoring and quantified potential low 
molecular weight biomarkers. Glucose has been used as a model to illustrate the strategy to 
isolate the relevant fraction of the sample to minimize the influence of the HMW proteins and 
improve the precision and accuracy of the quantitative models built using the PLSR 
algorithm. Initially, human serum spiked with systematically varying, physiologically 
relevant, concentrations of glucose will be used to optimise the measurement protocol, 
including a study of how the volume deposited on the ATR crystal influences the relevancy 
of the data collected. PLSR will be employed to build a predictive model over the 
concentration range to demonstrate the principle of the predictive capacity of the technique 
and the improved precision afforded by serum fractionation. In the second part of the study, 
the technique will be demonstrated in patient samples of known varying glucose levels, 
validating the potential for glucose level monitoring. 
  
2.  Experimental  
 
2.1 Materials and Methods 
 
Sterile, filtered human serum from normal mixed pool (off the clot) was purchased from TCS 
Biosciences (UK) for the in vitro model prepared from spiked solutions, while patient serum 
samples were donated by the University Hospital CHU Bretonneau de Tours (France), 
following the institutional ethical procedures. Initially, the samples were collected during 
routine blood check-ups, 1 mL of the vial remains being provided for further spectroscopic 
analysis. Commercially available, centrifugal filtering devices, Amicon Ultra-0.5ml 
(Millipore - Merck, Germany), with cut-off points at 10 kDa, were employed to fractionate 
the serum samples, in both cases. As a result, for each sample, 2 fractions were obtained 
following filtration; the first representing serum constituents with a molecular weight higher 
than the cut off point of the filter used (concentrate); the second corresponding to the fraction 
passed by the membrane and collected in the vial (filtrate). 0.5 mL of the serum was placed in 
the centrifugal filter for spinning. The procedure for washing the centrifugal devices prior to 
serum processing was adapted from
48, based on manufacturer’s guidelines, and performed as 
follows: The Amicon Ultra-0.5ml filter was spun thrice with a solution of NaOH (0.1M), 
followed by 3 rinses with Milli-Q water (Millipore Elix S). For both washing and rinsing, 0.5 
mL of the respective liquid was added to the filters and the centrifugation was applied for 10 
mins at 14 000g followed by a spinning with the devices upside down at 1000g for 2 mins in 
order to remove any residual solution contained in the filter.  
Additionally, D-Glucose (Fisher scientific, UK) was analysed as reference chemical 
compound for the quantitative analysis on whole and filtered human serum. Notably, glucose 
has been selected because it is routinely screened in clinics allowing determination of exact 
blood levels for each patient sample tested. 
 
2.2 Glucose Spiked Human Serum model 
 
The commercial whole human serum was supplemented with known concentrations of 
glucose; 0.0 mg.dL
-1
 (control), 20 mg/dL, 60 mg/dL, 100 mg/dL, 140 mg/dL, 180 mg/dL, 220 
mg/dL, in order to explore the dynamic range and sensitivities of the ATR-IR measurement 
of unprocessed and filtered samples. The concentrations have been selected to cover a wide 
range of physiological relevance to simulate hypoglycaemia (<60 mg/dL), normal level (70-
110 mg/dL) and hyperglycaemia (>120 mg/dL), in order to optimise the protocols for 
clinically relevant human serum monitoring using ATR-IR. The serum stock solution has 
been used as a reference to build the regression models and evaluate the sensitivity of the 
techniques.  
 
 
2.3 Patient samples blood glucose levels 
 
A total of 15 patient samples have been included in the present study. Glucose levels have 
been measured at the CHU de Tours using a Cobas analyser following the in house guidelines 
for routine biochemical analysis. The principle of the test is based on the enzymatic reference 
method with hexokinase, which catalyzes the phosphorylation of glucose to glucose-6-
phosphate by ATP
49, 50
. Subsequently glucose-6-phosphate is oxidized by glucose-6-
phosphate dehydrogenase, in the presence of NADP, to gluconate-6-phosphate. This reaction 
is specific, with no other carbohydrate being oxidized. The rate of NADPH formation during 
the reaction is directly proportional to the glucose concentration and is measured 
photometrically in the UV. 
Glucose level is one of the most common tests performed during blood check-ups and is 
therefore a perfect model to develop a proof of principle for quantification of low molecular 
weight biomarkers in human serum using ATR-IR spectroscopy. The instrumentation 
available at CHU de Tours has a standard deviation of 0.04 mmol.L
-1 
(0.721 mg.dL
-1
), and 
can therefore be considered as the gold standard. Measured glucose concentrations were 
provided with the patient samples and have been used as target values for the PLSR models. 
A summary of information extracted from patient histories is given in Table 1 (see below).  
 
    
 
Table 1: Summary of patient’s information 
Sample 
number 
Glucose blood levels 
Gender Age mmol.L
-1 
(+/- 0.04) 
mg.dL
-1 
(+/- 0.721) 
1 3.4 61.25 F 33 
2 3.5 63.05 F 36 
3 3.6 64.86 F 64 
4 3.7 66.66 M 31 
5 3.7 66.66 F 30 
6 3.7 66.66 F 87 
7 3.8 68.46 F 26 
8 6.4 115.3 M 73 
9 6.5 117.10 M 65 
10 6.7 120.70 F 58 
11 7.0 126.11 M 75 
12 7.3 131.51 M 53 
13 9.5 171.15 M 79 
14 10.0 180.16 F 63 
15 11.6 208.98 M 63 
 
 
2.4 Data collection using the ATR-IR  
 
ATR-IR spectra were recorded using a Bruker vector 22 equipped with a a single reflection 
golden gate ATR accessory (Specac, UK). A diamond top plate with a 45°C incident angle 
was preferred for this study. Sample depth penetration of the evanescent wave is both 
wavenumber and sample dependent, but is typically on the order of 1µm. Spectral data were 
the result of 32 scans, with a spectral resolution of 4 cm
-1
 covering the spectral window 4000 
– 600 cm-1. A background spectrum was also recorded in the air (32 scans) and automatically 
ratioed with the sample spectrum by the software. A built-in quality control is automatically 
performed by the operating system (OPUS software) every day at the system start up 
ensuring the ATR accessory is delivering adequate data and not malfunction of the 
instrument is detected.      
Liquid human serum solutions: The spectroscopic analysis of samples was performed directly 
after deposition of a drop on the crystal (0.1 µl, 0.2 µl, 0.5 µL, 1 µL and/or 2 µl), following 
air drying. The drying time necessary is directly related to the volume deposited and can be affected 
by external parameters such as room temperature and humidity but it is generally comprised between 
3-5 mins. “Moreover, the effectiveness of the air drying has been confirmed in real time following the 
evolution of the main water band in the range 4000-2500 cm
-1
 directly on screen. The broad water 
band, with a maximum absorbance between 3270-3340 cm
-1
, is a reliable indicator of the dehydration 
of the sample deposited. The intensity of the band would gradually decrease as the sample is drying 
until reaching an equilibrium with no more spectral variations observed. When the signal has been 
found stable over at least 60 seconds, the drop has been considered dry and the spectra were collected. 
Although not yet automated and requiring the constant presence of the operator to monitor the screen, 
this approach has been found particularly efficient and the complete drying can be unambiguously 
confirmed in the data collected, as illustrated with the raw spectrum in Figure 1B.”    
At least 5 drops have been measured per sample and sets of 5 spectra have been collected for 
each drop in order to take into account both instrumental and inter-drop variability. In order 
to reduce the inter-drop size and shape variability, the deposition has been made on clean and 
dry crystal. It has been observed that the top diamond plate is quite hydrophobic avoiding the 
drop to spread out after deposition maintaining the round shape of the liquid sample. All 
drops have been made with micropipettes and perpendicularly to the surface which ultimately 
resulting in reproducible circular shaped samples centred on the crystal after air drying. 
Finally, only 20 spectra (4 drops) have be used for each sample, selecting the data sets with 
similar raw maximum absorbance indicating the solutions have been deposited similarly on 
the crystal. Ultimately, a total of 140 spectra were included in the model study with spiked 
human serum, while 300 spectra were analysed for the 15 patient samples. 2 µL has been 
found to be the maximum realistically usable volume, considering the drying time and the 
large number of samples tested.    
 
2.5 Data pre-processing and analysis 
 
The different pre-processing and data analysis steps were performed using Matlab 
(Mathworks, USA). Partial Least Squares Regression (PLSR) analysis was exploited as an 
approach to quantify the spectral variability generated by either the addition of known 
concentrations of glucose to the human serum or estimate blood glucose levels in patient 
samples. 
The analysis of the spectra collected has been restricted to the finger print region, in which 
the sugar contribution occurs in IR spectra. The spectra collected from spiked human serum 
have been either min-max normalized (MMN) at the 1637 cm
-1
 peak corresponding to the 
amide I band or processed using baseline correction (rubber-band) followed by vector 
normalization (VN). It should be noted that, following filtration, the spectral signature is 
quite different, due to the depletion of the abundant proteins. Consequently, the typical 
Amide I and II bands are not observed in the filtered serum, but are replaced by a strong peak 
at 1591 cm
-1
 most likely assigned to conjugated C=C. For consistency, this band, which is the 
most intense observed in the spectra of the filtered samples, and is also remote from the 
glucose bands, has been selected for the min-max normalisation.  
In an attempt to preserve the information related to raw absorbance intensity, a different 
method has been employed for the data collected from patient samples. Due to the fact that 
none of the spectral features is consistent between patients, and thus cannot be used as 
internal standard, the min-max normalisation on the amide I band was found to be 
insufficient (data not shown). However in order to minimise the slight drifts observed the 
spectra background it has been preferred to normalised the data at 1780 cm
-1
, located in a 
region away from any IR bands of the serum.
 
This approach was evaluated in this study to 
compensate from the offsets observed in the raw data, restoring a common baseline for the 
spectra without losing the relation between absorbance and the concentrations of different 
molecular species. The PLSR model has been built from the pre-processed data sets. The 
algorithm works in a supervised fashion, whereby all different concentrations are known 
before running the analysis. Ultimately, the output gives an estimation of the model precision 
(Root Mean Square Error – RMSE) and linearity between the experimental and predicted 
concentrations (R
2
). In order to validate the robustness of the models, a 20 fold - cross 
validation loop has been included in the routine. For each iteration, 50% of the data is 
randomly selected to constitute the calibration set, while the remaining 50% are used as a 
validation set for the quantitative predictions. In the present study, particular attention has 
been accorded to exploit the entire outcome of the PLSR models. For this, for each iteration 
of the cross validation the RMSE, R
2
 and predicted concentrations have been extracted and 
compiled to calculate mean and standard deviations values.   
  
3.  Results and discussion 
 
3.1 Quantification of Glucose levels in spiked human serum   
3.1.a Selecting volumes deposited 
 
 
Figure 1: Typical ATR IR spectra collected from a 2 µL drop of 10 g.dL-1 pure glucose solution deposited on the ATR 
crystal (A) and human serum (B). Both spectra have been recorded after air drying. No preprocessing has been applied. The 
spectra have been offset for clarity and the main features of interest in the serum spectrum are highlighted.      
 
 
ATR-FTIR appears to be a convenient, rapid and reliable approach to collecting high quality 
spectra from highly concentrated liquid samples such as human body fluids and for instance 
serum
51
. A drop directly deposited onto the crystal can be anaysed without prior dilution to 
avoid saturation effects generally encountered with transmission mode measurements
52
. 
Despite the rich compostion of the human serum, the water contribution remains quite intense 
in the data gleaned from liquid form samples and air drying remains preferable to visualise all 
the spectral features
53
. Figure 1 presents ATR-IR spectra collected from an air dried aqueous 
solution of glucose (10 gdL
-1
) (Figure 1A) and human serum (Figure 1B). Following air 
drying, the human serum spectrum displays numerous well defined peaks within the 4000-
650 cm
-1
 spectral widow, allowing clear identification of specific features of the human 
serum, for example those highlighted in grey at 3280 cm
-1
 (H–O–H stretching), 2957 cm-1 
(Asymmetric CH3 stretching), 2920 cm
-1
 (Asymmetric CH2 stretching), 2872 cm
-1
  
(Symmetric CH3 stretching), 1536 cm
-1
 (Amide II of proteins), 1453 cm
-1
 (CH2 scissoring), 
1394 cm
-1
 (C=O stretch of COO–), 1242 cm-1 (Asymmetric PO2 stretch), 1171 cm
-1
 (Ester C–
O asymmetric stretch) and 1080 cm
-1
 (C–O stretch)53-55. The spectrum from whole human 
serum is clearly dominated by the abundant proteins contribution such as albumin and 
globulins
24
 which swamp the contribution of less represented biomolecules. In comparison, 
the glucose signature exhbits fewer features, the main peaks being located in the spectral 
range 1280 – 800 cm-1, resulting from both the ν(C—O) and ν(C—O—C) vibrational 
modes
56
, as identified in Figure 1A.  In the present work, the limited spectral window of 1800 
– 900 cm-1 was chosen to avoid the regions of strong water absorption. Although the spectral 
response has stabilised, contributions of water are still visible as a broad background in the 
region of ~3300cm
-1
.   
 
 
 
Figure 2: Evolution of Area Under the Curve (AUC) of the band at 1180-955 cm-1 as a function of volume of glucose 
solution deposited. Red: 10 g.dL-1 glucose solution ; Blue: 0.1 g.dL-1 glucose solution. Intensity of the blues bars have been 
multiplied by 5 for better visualization on the graph. Error bars are the results of 5 independent measurements. 
 
The volume deposited can have a influence on the data collected, depending on the 
concentration of the solutions analysed and the coverage of the crystal achieved. The so-
called “coffee ring effect” has been documented extensively in literature53, 57 and describes 
the uneven distribution of the constituents following air drying. Commonly, a higher 
concentration is obtained on the edge of the deposited material which can result in some 
spectral variability. In complex mixtures such as human serum, different chemical 
constituents are deposited at different rates, as descibed by Vroman
58
, resulting in spatially 
inhomogeneous chemical composition in the dried deposit. Figure 2 presents the dependence 
of the area under the curve observed in raw data (AUC – between baseline and peak 
maximum), calculated for the band 1180-955 cm
-1
, depending on deposited volume, for two 
different concentrations of glucose solution. The 10 g.dL
-1
 solution does not exhibit any 
noticeable decrease in the AUC between 0.5 µL and 2µL, explained by a full coverage of the 
crystal coupled to a saturation of the signal
24
. The notion of saturation is defined by the loss 
of linearity between the absorbance and the concentrations measured. In opposition to 
transmission IR spectroscopy which can deliver absorbance up to 3 with a saturation 
manifesting itself with highly noisy spectra coupled to plateau effects, ATR-IR spectra 
intensities are limited by the depth of penetration of the evanescent wave. In the present study 
and considering the instrumentation used, it has been observed that the maximum absorbance 
that can possibly be recorded from protein rich samples such as human serum would never 
exceed 0.45. Following air drying, the Beer-Lambert type dependence of the absorbance on 
initial sample concentration and length of the optical path can both be partially lost and the 
critical parameter is the amount of matter deposited. In other words, the deposited sample 
thickness, and therfore absorbance, depends on the concentration of the droplet applied, but if 
the sample thickness exceeds the evanescent wave penetration depth, no further increase in 
the absorbance can be observed. However, when reducing the volume below 0.5 µL, the 
deposit thickness becomes less than the sampling depth, and the AUC consequently 
decreases. The AUC pattern for the 0.1 g.dL
-1
 is rather different, a maximum intensity being 
found with 0.2 µL. This is a result of the coffee ring effect, as the glucose is accumulated in 
the edges of the drop, outside the field of data collection for larger volumes (Figure 2, 0.5 µL 
– 1 µL – 2 µL ), thus delivering poor signals, while the 0.2 µL deposit is completely 
contained on the crystal and entirely recorded. The decrease observed for the 0.1 µL sample 
confirms that the drops are smaller than the ATR crystal area. Further investigations of 
human serum have been performed with both 2 µL and 0.2 µL. Although 0.1 µL would have 
been optimum to ensure the volume deposited is smaller than the crystal size, due to the 
viscosity of the serum, the smallest volume that could be deposited as drops was 0.2 µL.  
 
 
3.1.b Construction of the quantitative model: Partial Least Square Regression (PLSR) 
 
    
 
   
Figure 3: Mean ATR-IR spectra collected from unprocessed whole human serum (red) and supplemented with 20 mg/dL 
(blue), 60 mg/dL (green), 100 mg/dL (yellow), 140 mg/dL (black), 180 mg/dL (magenta) and 220 mg/dL (cyan) of glucose 
respectively. A: Finger print region 1800-900 cm-1; B: Glucose region 1190 – 900 cm-1. Min-Max normalized spectra on the 
amide I band (1637 cm-1) used for illustration. 
 
 
Before analysing the patient samples, a quantitative model has been built using the PLSR 
algorithm and applied to the glucose spiked human serum models in order optimise the 
protocol for measurement, including deposit volume, and to evaluate the impact of 
centrifugal filtration on the sensitivity and accuracy of the technique.  
The first step of the study was to build a model accurately mirroring clinically relevant blood 
variations of glucose levels using human serum spiked with D-glucose. For this, different 
amounts of pure glucose have been added to the human serum stock solution in order to 
achieve variable concentrations in the physiologically relevant range of 20 mg/dL – 220 
mg/dL. The normal glucose concentration being between 70 mg/dL and 110 mg/dL, 
simulation for hypoglycemia and hyperglycemia have been deliberately included in the set of 
samples prepared and tested. Figure 3A presents mean ATR-IR spectra collected following 
air drying from the different solutions. The (1637cm
-1
) min-max normalized data exhibit 
similar profiles, only the region attributed to sugar being affected by the increase of glucose 
concentration. In Figure 3B, it can be observed how the 1140 – 950 cm-1 spectral region 
evolves from the serum stock solution (red) to the highest concentration prepared (cyan), the 
main features at 1105 cm
-1
, 1078 cm
-1
, 1032 cm
-1
 and 989 cm
-1
 systematically increasing with 
glucose concentration.           
 
 
 
Figure 4: First (A) and second (B) PLS weighting vector corresponding respectively to dimension 1 and 2 of the scatter 
plot. Min-Max normalized spectra on the amide I band (1637 cm-1) used for illustration. 
  
Preprocessed spectra have been analyzed using the PLSR algorithm to determine the 
relationship between spectral variations and glucose concentrations. The method being 
supervised, the different concentrations are taken into account during the calculations. The 
first step generates a scatter plot, (not shown). Figure 4 presents the first two weighting 
vectors A and B, confirming the discrimination of the data is based on glucose features, 
which, as demonstrated in Figure 2/3, mainly occur in the 1190-950 cm
-1 
window. The 
similarities between the 2 weighting vectors support the fact that more than 1 dimension is 
required to fully describe the spectral variability due to glucose concentrations. Plotting the 
Root Mean Square Error from the validation set (RMSEV) as displayed in Figure 5 is 
commonly used to guide the operator in choosing the optimal number of dimensions 
necessary to reach the best model. In the present case, a 20 fold cross validation has been 
preferred, leading to the creation of 20 independent calibration/validation sets and thus 20 
preictive models. In order to simplify the illustration, the error bars in Figure 5 illustrate the 
standard deviation calculated between each iteration of the cross validation. As expected, a 
strong decrease in the RMSEV is observed within the 3 first dimensions, which is normal 
behaviour for well discriminated data, followed by a stabilisation of the values observed 
without any further improvement of the model precision. Considering the min-max 
normalised spectra used for illustration in Figure 5, a minimum is found at 2.078+/-0.252 
mg/dL, corresponding to 8 dimensions. For consistency between data sets, the minimum 
found has always been selected to build the predictive models. It should be noted that similar 
plots can be obtained from the RMSE for the Calibration sets (not shown).  
 
Ultimately, after selection of the optimal number of dimensions for the data set analysed, a 
predictive model can be built from the PLSR scatter plot (Figure 4), to compare the 
observations corresponding to the known concentrations of glucose in the samples with the 
estimated concentrations from the spectral data sets. In the example presented in Figure 6, a 
really good linearity was reached, with a R
2 
value of 0.9992. The standard deviation (2.172e
-
4
) is indicative  of good repeatability between the 20 iterations of the cross validation. 
However, the standard deviation of the RMSEV (0.2526 mg.dL
-1
) is equal to about 10% of 
the mean value, but remains accepTable considering the precision of the model is below the 
mg.dL
-1
 range. Moreover, the error bars display no overlapping of data, indicating that each 
concentration can be unambigiously identified. This approach has been replicated for all data 
sets collected from the human serum samples spiked with glucose, either unprocessed (whole 
serum) or following centrifugal filtration with a 10 kDa device. The summary of the PLSR 
results is presented in Tables 2 and 3.  
 
 
Figure 5: Evolution of the root mean square error on the validation set (RMSEV) according to the number of dimensions 
selected in the PLS model. Value are average calculated from the 20 iteration of the cross validation associated to 
corresponding error bar illustrating the standard deviation. Min-Max normalized spectra on the amide I band (1637 cm-1) 
used for illustration. 
 
 
 
Figure 6: Predictive model bluid from the PLS analysis. For each cocentrations the value displyed is an average of the 
concentration predicted with the corresponding standard deviation calculated from the 20 iterations of the cross validation. 
Mean RMSEV and R2 values are given on the plot both also with their respective standard eviation. Min-Max normalized 
spectra on the amide I band (1637 cm-1) used for illustration. 
 
 
3.1.c Summary of results from unprocessed whole human serum spiked wih glucose 
 
As detailed in Figure 2, the deposition of 2 µL and 0.2 µL drops has been used to illustrate 2 
distinct experimental conditions corresponding to a coverage exceeding the ATR crystal, 
after air drying of the samples, compared to a coverage less than the recording area. The 
objective is to better understand how the volume of the deposit can influence the relevancy of 
the data collected, notably in relation to the coffee ring effect. It has been been documented 
that such an effect can result in variations of the distribution of molecular species.      
A direct comparison of the predictive results obtained from 2 µL and 0.2 µL (Table 2) drops 
of whole human serum unambiguously demonstrates that the precision of the PLSR models is 
strongly affected by the size of the drops. The best RMSEV (2.078+/-0.252 mg.dL
-1
) was 
achieved with the Min-Max Normalised (MMN) ATR-IR spectra collected from the 2 µL 
drops, while this value is up to 6 times higher for the 0.2 µL deposits (12.347 +/- 1.852 
mg.dL
-1
). It should be noted that neither reducing the spectral range of the glucose windows 
(1190-950 cm
-1
) (See Table 2 GLU) nor using vector normalisation (VN) improves the 
precision of the predictive models. (See Table 2 VN) 
This observation is rather encouraging and supports the notion that, although the samples 
exhibit a heterogeneous distribution of the different molecular species following air drying, 
the centre of the drop still delivers quantitative information that can be linearly captured by 
the PLSR models.  
Interestingly, the 0.2 µL does not improve the PLSR quantitative model, which suggests that 
attempting to ensure that the entire sample is deposited on the ATR crystal, with a coverage 
less than the recording area, is not the best strategy when performing ATR analysis. An 
experimental limitation of ATR-IR spectroscopy is the absence of a bright field imaging 
system coupled to the spectrometer, making the visualisation of the drop positions quite 
difficult, especially with volumes less than 1 µL. Therefore, it is simply impossible to ensure 
the 0.2 µL samples have been positioned identically on the ATR crystal, explaining the high 
RMSEV values. 
 
 
   Table 2: Summary of PLS results for the unprocessed human serum analysis 
Deposit type Drop - 2 µL Drop - 0.2 µL 
 
RMSEV STD R
2
 RMSEV STD R
2
 
MMN 
FP 2.078 0.252 0.999 12.347 1.852 0.974 
GLU 2.388 0.126 0.999 15.419 0.753 0.96 
VN 
FP 2.137 0.181 0.999 12.512 1.36 0.973 
GLU 2.806 0.362 0.999 15.942 2.058 0.956 
MMN: min-max normalised at 1637 cm-1; VN: baseline and vector normaised, STD: standard deviation, GLU: spectra cut to the range 
1190-950 cm-1  
 
3.1.d Summary of results: 10 kDa filtered human serum spiked with glucose 
 
Centrifugal filtration has been used to fractionate the human serum and isolate chemical 
populations depending on their molecular masses. In the present study, a 10 kDa centrifugal 
device was used in order to specifically deplete the abundant proteins such as globulins and 
albumin
24
 and retain only the molecular species with low molecular weight in the filtrate, 
below the cut off point of the membrane, for subsequent spectroscopic analysis. For instance, 
glucose is about 180 Daltons, which means it will freely pass through the membrane during 
spinning of the human serum. Using such an approach, the complex mixture of the human 
serum can be partially simplified, removing some of the most dominant proteins such as 
albumin and globulin, consequently enhancing the contribution of underlying constituents in 
the IR signatures collected as illustrated in Figure 7.   
 
 
 
Figure 7: Mean ATR-IR spectra collected from human serum stock solution unprocessed whole (A) and 10 kDa (B) in the 
finger print region 1800-900 cm-1. Spectra offset for clarety 
 
 
For the 10 kDa filtered serum model, the measurement of deposits from the 2 µL drops 
deliver the best predictive model with a RMSEV value of 2.199±0.250 mg.dL
-1
 for the MMN 
data. As for the unprocessed whole human serum, no improvement can be obtained with 
deposits from smaller volumes (0.2 µL), but rather an increased RMSEV of 5.337± 0.551 
mg.dL
-1
 is observed, indicating once more that precision in the sample deposition on the ATR 
crystal is a crucial aspect for this experimental set up. However, as witnessed earlier, the 
centre of the dried samples preserve the linear relation between glucose concentrations and 
spectral variations. This is a significant observation as, following the centrifugal filtration, the 
overall concentration of the serum filtrate is strongly diminished due to depletion of the 
abundant proteins. The thickness of material deposited from the same volume is therefore 
significantly reduced, potentially below the region of saturation of the STR sampling (Figure 
2). The high degree of variability in the raw spectral intensities is compensated by the 
normalisation of the data prior to PLSR analysis. Ultimately, ,values of the RMSEV of 
2.078±0.252 mg.dL
-1
 and 2.199±0.250 mg.dL
-1
 for, respectively, the unprocessed and filtered 
serum are not significantly different, within the standard deviation associated with them 
(Table 3).  
This initial step of the study is rather reassuring, indicating that centrifugal filtration does not 
affect the sample integrity, which remains representative of the concentrations of the different 
serum physiological constituents. The main concern was regarding the drying pattern of 
biological samples characterised by low concentrations, as illustrated in Figure 2, which are 
more affected by the coffee ring effect which could result in a drastic decrease in the IR 
spectral intensity due to accumulation of molecules in the edge of the dried drop, with little or 
no contribution at the centre of it. However, despite the considerably reduced concentration 
in filtered serum, this effect remains limited and the recordings performed on the 2 µL drops 
are perfectly relevant, delivering good predictive models by means of PLSR analysis. 
Following those observation, the use of 0.2 µL samples can be disregarded for analysis of 
patient samples, in favour of the 2 µL.    
 
 
 
 
  
  
 
 
Table 3: Summary of PLS results for the 10KDa filtered human serum analysis 
Deposit type Drop - 2 µL Drop - 0.2 µL 
 
RMSEV STD R
2
 RMSEV STD R
2
 
MMN 
FP 2.199 0.250 0.999 5.337 0.551 0.995 
GLU 3.465 0.317 0.998 5.506 0.417 0.995 
VN 
FP 2.679 0.234 0.998 5.357 0.396 0.995 
GLU 4.001 0.337 0.997 8.746 0.539 0.986 
MMN: min-max normalised at 1591 cm-1; VN: baseline and vector normaised, STD: standard deviation, GLU: spectra cut in range 1190-
950 cm-1  
 
3.2 Glucose level quantification in patient samples 
Although the quantitative capabilities of ATR-IR spectroscopy can be quite easily 
demonstrated with model human serum spiked with glucose, both purchased online, the 
analysis of patient samples can be considered a more delicate matter, the main reason being 
the multi-parametrical variability observed in clinical applications. When spiking human 
serum with glucose, only one physiological constituent is affected, while all others remain at 
similar levels. In that situation, any peak away from the glucose spectral window can be used 
as an internal standard for calibration of the data, explaining the good results obtained with a 
MMN to the amide I band. The overall protein content being the same between spiked 
samples, the multivariate analysis of the spectra ultimately highlights the linear evolution of 
the band ratio between the proteins and glucose. However, samples harvested from patients 
can display an intrinsic variability, directly reflecting their physiological state on the day. In 
real conditions, there is no real control, as each individual has it own metabolism, 
characterised by different ground blood levels for all the serum constituents. Uric Acid, 
Blood Urea Nitrogen (BUN), Creatinine, total proteins (albumin, globulin), Total Bilirubin, 
Alkaline Phosphatase, GGTP, LDH, SGOT (also called AST) are some of the most screened 
serum constituents, although only a few are routinely tested. Glucose is indeed one of them, 
used for monitoring either hypoglycaemia or hyperglycaemia, particularly important for the 
detection of diabetes. In addition to the fact that glucose can freely diffuse through the 
centrifugal device membranes and be fully collected in the filtrate, the choice of the glucose 
was also motivated because of its physiological relevance and normal levels in human serum. 
With concentrations ranging between 70-100 mg/dL, it can be detected in whole unprocessed 
serum, which was the condition required to be able to build a comparative model between 
patients samples before and after fractionation. 
A total of 15 patient samples have been analysed using ATR-IR spectroscopy, selected to 
cover a wide range of glucose concentrations mirroring cases of hypoglycaemia and 
hyperglycaemia (Table 1). The initial measurements have been performed from the 
unprocessed samples, as provided from the clinician, from 2 µL air dried drops. Similarly to 
the spiked samples, the spectra, min-max normalised at 1780 cm
-1
, have been analysed with 
the PLSR algorithm and the results are presented in Figure 9_TOP. With a RMSEV of 11.87 
+/- 0.88 mg/dL, the precision of the predictive model has strongly decreased in comparison to 
the observation made from spiked serum. Furthermore, the R
2
 reflects the lack of linearity 
between the spectral variations and the glucose levels, thus the poor quality of the analysis 
performed. As shown in Figure 8, although the first (A) and second (B) PLSR weighting 
vectors contain contributions which can be associated with glucose (Figure 1), there are also 
significant other contributions associated with serum proteins in the region 1650-1350 cm
-1
. 
Following the first set of measurements, the same patient samples have been processed with a 
10 kDa centrifugal device in order to fractionate the serum by depletion of the abundant 
proteins. From the resulting filtrates, ATR-IR spectra have been recorded, also min-max 
normalised at the 1780 cm
-1
 and analysed in identical conditions for comparison purposes. 
The PLSR model is presented in Figure 9_BOTTOM, displaying a much better RMSEV 
value (3.1 ± 0.13 mg.dL
-1
). A comparison of both plots unambiguously supports the 
improvement after centrifugal filtration that can be achieved, confirmed by the reduced 
standard deviation associated with each concentration tested. Consequently, the linearity of 
the predictive model is restored to an accepTable value for R
2
 of 0.9957. The first (A) PLSR 
weighting vector, shown in Figure 8, still contrains significant contributions associated with 
serum proteins in the region 1650-1350cm
-1
, although the spectrum (B) of the second is now 
dominated by glucose.  
 
 
 
Figure 8 : Evolution of the root mean square error on the validation set (RMSEV) according to the number of dimensions 
selected in the PLS model with corresponding first (A) and second (B) PLS weighting vector corresponding respectively to 
dimension 1 and 2 of PLSR model. TOP: unprocessed serum; BOTTOM: 10 kDa filtered serum. 
 
    
Table 4 gives an overview of the different predicted concentrations for each patient for both 
unprocessed and fractionised samples. The mean values from the 20 cross validations 
iterations are given in mg/mL with the corresponding standard deviation and finally the 
relative error compared to the real glucose concentration, as given by the clinician, has been 
expressed in percentage. Ranging from 16.39% to 0.25%, the relative error for the 
unprocessed serum clearly highlights the difficulties to estimate the glucose levels in whole 
serum. Indeed some of the samples display accepTable mean predictive values because of the 
supervised fashion of the PLSR algorithm. As for any calibration curve, the trend line 
illustrates the best fit between data point, meaning few samples are located close to it. In 
comparison, the filtered serum delivers higher accuracy, ranging from 2.51% to 0% mean 
relative error. Looking at the samples independently, it can be seen that the majority of them 
are below 1% relative error, clearly supporting the increased accuracy of the model with 
fractionated samples. 
 
 
 
 
Figure 9: TOP: Predictive model built from the PLS analysis of patient unprocessed samples. For each concentrations the 
value dysplayed is an average of the concentration predcited with the corresponding satandard deviation calculated from 
the 20 iterations of the cross validation.  Mean RMSEV and R2 values are given on the plot both also with their rexpective 
standard eviation. Min-Max normalized at 1780 cm-1. 
BOTTOM: Predictive model built from the PLS analysis of patient 10kda filtered samples. For each concentrations the 
value dysplayed is an average of the concentration predcited with the corresponding satandard deviation calculated from 
the 20 iterations of the cross validation.  Mean RMSEV and R2 values are given on the plot both also with their rexpective 
standard eviation. Min-Max normalized at 1780 cm-1 
 
Considering the complexity of human serum, concerns can be raised towards the monitoring 
of low molecular weight physiological constituents potentially relevant for diagnosis. The 
proof of principle presented throughout this study demonstrates that glucose levels, a well 
known biomarker for diabetes, can be monitored by means of infrared spectroscopy. As 
highlighted in Figure 1, specific spectral features can be identified for the detection of 
glucose in complex biological mixtures. Moreover, using multivariate analysis tools such as 
PLSR, a linear relation between glucose levels and the intensity of glucose spectral features 
can be obtained. The interferences presented by the HMWF of the human serum is illustrated 
in the case of patient samples (Figure 9), indicating that the presence of the abundant proteins 
can be identified as a limiting factor when focusing the spectral analysis of potential low 
molecular weight biomarkers. Similarly to glucose, the constituents of the LMWF of the 
serum can exhibit weak contributions in the IR data collected directly impacting on the 
precision and accuracy of the quantitative models developed. The concept of human serum 
fractionation proposed in the present work, implies that separating the fractions of interest to 
perform spectral characterisation independently would ultimately lead to better accuracy. 
Instrumentation available in clinics present high performance towards glucose level 
monitoring, and with a standar deviation of 0.72 mg.dL
-1
 (0.04 mmol.L
-1
), it is hardly 
conceivable that IR can deliver better results. Although with a RMSEV of 3.1 +/- 0.13 
mg.dL
-1
, fractionating the human serum before analysis places the ATR-IR approach in a 
clinically relevant range of concentrations allowing the identification of patients with 
abnormal glucose levels (either hypo- or hyper-glycaemia), the aim of the work proposed was 
to further demonstrate the potential for body fluids screening towards disease diagnosis, in 
general. “However, the detection and monitoring of biomarkers can be subjected to 
requirements specifically defined by the clinicians. For instance, when considering blood 
glucose the concept of Parkes error grid has been implemented in 1994
59
. This model defines 
performances zones for the results collected aiming to assess clinical accuracy for BG 
monitoring devices. Notably the Parkes error grid has been introduced as an accepted evaluation tool 
in ISO15197:2013 guideline “In vitro diagnostic test systems -- Requirements for blood-glucose 
monitoring systems for self-testing in managing diabetes mellitus”. Example of Parkers error grid 
constructed from the PLSR analysis performed from whole and filtered patient serum are given in 
supplementary material Figure S.2. Each estimated values from both PLSR models (3000 predicted 
concentrations) have been plotted in order to better visualize their distribution between the risk zones 
(to be noted that the model is based on Diabetes type I). While for the whole serum a majority of the 
values are found into the zone A, defined as the zone of “clinical accurate measurements with no 
effect on clinical action”, it can also be observed that for the lowest concentrations many are located 
in the zone B. A general consensus would support that based on the definition of the risk boundaries, 
a clinically accurate BG meter should show at least 95% of its data points in zone A of the Parkes 
grid. Also the number of patient in the present study remains limits it is however interesting to witness 
the great improvement obtained after depletion of the abundant proteins by ultrafiltration and how all 
the predicted concentrations from the PLSR model are now gathered in the zone A, lifting any 
unambiguously about the data interpretation. This further supports the increased clinical 
relevancy of the quantitative measurement performed after isolation of the LMW fraction.”   
 Recently, an increasing numbers of publications promote the capabilities of IR and Raman 
spectroscopy for serum analysis in both animal and human models from cardiovascular 
disease to cancers diagnosis
60-62
. However even facing the difficulties to accurately perform 
specific discrimination or diagnosis
2, 52
, resorting to pre-analytical sample preparation 
procedures is rarely or never considered. Ultimately, the benefits of serum fractionation using 
centrifugal filtration demonstrated in the case of glucose levels can be easily transferable to 
any other low molecular weight biomarkers with swapped contribution in the IR data by the 
HMWF. Therefore such optimisations would contribute to further broaden the range of 
applications of vibrational spectroscopic techniques.   
 
 
Table 4: Summary of PLS results for the unprocessed and 10 kDa filtered human serum 
patient samples. 
 
Unprocessed serum 10 kDa Filtered serum 
Predicted concentrations (mg/dL) 
Patient 
Concentrations 
(mg/dL) 
Mean STD % M STD % 
1 61.25 65.39 9.84 6.75 61.68 2.45 0.71 
2 63.05 52.71 11.46 16.39 63.05 3.74 0.00 
3 64.86 70.34 7.59 8.45 65.37 2.73 0.78 
4 66.66 73.44 10.69 10.17 65.66 3.04 1.51 
5 66.66 66.94 10.98 0.42 67.16 2.68 0.76 
6 66.66 67.04 9.90 0.58 67.02 3.66 0.55 
7 68.46 73.71 7.62 7.67 70.18 3.33 2.51 
8 115.3 116.54 8.49 1.08 112.92 2.65 2.06 
9 117.1 112.04 10.04 4.32 116.30 2.42 0.69 
10 120.7 115.32 8.68 4.46 122.65 1.90 1.61 
11 126.11 127.20 7.44 0.86 126.64 2.89 0.42 
12 131.51 126.72 8.91 3.64 131.43 3.39 0.06 
13 171.15 175.12 9.48 2.32 171.44 2.50 0.17 
14 180.16 180.61 7.16 0.25 179.03 2.77 0.63 
15 208.98 202.37 9.66 3.16 209.01 3.00 0.01 
STD: standard deviation; %: relative error between referecence and mean predicted value expressed in percent  
 
   
4.  Conclusion 
Screening of human serum, and by extension all body fluids, is still an emerging field of 
application and in order to strengthen the position of Infrared spectroscopy as a potential 
clinical tool, numerous questions need to be considered and addressed by the community. 
Firstly, the technique should be competitive with other approaches currently used, such as 
Mass spectroscopy, in terms of sensitivity and specificity, and, secondly, it should be able to 
deliver information relevant for clinical diagnosis. Infrared spectroscopy holds immense 
promise for the implementation of new quantitative analytical techniques in clinical routines. 
The label free/reagent free argument is often used to further support the relevancy to develop 
such techniques. However, in order to comply with the high requirements associated with 
body fluids based diagnostics, a number of improvements of the experimental protocol can be 
proposed. Notably, delivering quantitative information of the different serum constituents is 
crucial to validate the approach as a potential clinical tool. Centrifugal filtration of human 
serum has been proposed to specifically isolate relevant fractions of the samples for more 
accurate spectroscopic analysis. Using glucose as an example, it has been clearly illustrated 
that the depletion of the abundant proteins has greatly reduced the spectral variability and 
consequently significantly improved the precision and accuracy of the quantitative models for 
potential low molecualr weight biomarkers built from the PLSR analysis. In the present 
study, it has been highlighted that the patients samples are characterised by a normal 
variability, reflecting the physiological state of the individuals tested, but also that such 
effects can be considerably reduced by means of easy and rapid pre-analytical samples 
preparation steps. Furthermore, as the sample processing is also applicable to a wider range 
of body fluids, the methodology presented in the present work will certainly be beneficial for 
the field and lead to drastic improvements in the strategies oriented toward their 
implementation as the next generation of diagnostics techniques clinical tools.     
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